ライフサイエンスコーパス: Johnson

1 Johnson & Johnson stents were implanted in the SVGs of 1

2 Johnson & Johnson; HIV Vaccine Trials Network; Division

3 Johnson and Johnson, Sputnik Light, and Moderna vaccines

4 Johnson and Wardle review the effects of palatability an

5 Johnson et al. show that the receptor-binding domain of

6 Johnson S, Bobb JF, Ito K, Savitz DA, Elston B, Shmool J

7 Johnson was missing the middle initial.

8 Johnson-Kendall-Roberts (JKR) contact mechanics test was

9 Johnson-Lindenstrauss (JL) matrices implemented by spars

10 Johnson-Mehl-Avrami-Erofeyev-Kholmogorov (JMAEK) and the

11 (Johnson-Neyman interval in the IHS sample, -0.02, 0.71;

12 6; Faust et al., 1977; Hirsch and Han, 1969; Johnson and Hirsch, 1972).

13 ransducer--beyond the measured 800 pV Hz-1/2 Johnson noise of the resonant circuit--consists of the q

14 Jacksonville, FL) and etafilcon A (Acuvue 2; Johnson & Johnson Vision Care) lenses were all soaked fo

15 -1273 vaccine or 1 dose of the JNJ-78436735 (Johnson & Johnson) vaccine.

16 requency (f(T)/f(max)) of 140/215 GHz, and a Johnson's figure-of-merit (JFOM) of 5.04 THz V is simult

17 etric halogenation of a simple alkene, and a Johnson-Claisen rearrangement that generates a quaternar

18 .1.0.0(2,4)]heptane, that is formed during a Johnson-Corey-Chaykovsky reaction on a cyclopentenone.

19 Instead, a Johnson-Mehl-Avrami-Kolmogorov model of perimeter-depend

20 Janssen Research & Development, LLC, a Johnson & Johnson company.

21 With these parameters, a Johnson-Kendall-Roberts-like scaling of the separation f

22 th receptor molecules are calculated using a Johnson, Kendall, and Roberts contact mechanics model.

23 Acemoglu, Johnson, and Robinson (abbreviated AJR) established the

24 rofloxacin-HCl-soaked Acuvue lenses (Acuvue; Johnson & Johnson Vision Care, Inc., Jacksonville, FL).

25 (Bausch & Lomb, Rochester, NY) and Acuvue2 (Johnson & Johnson, New Brunswick, NJ) soft contact lense

26 ochester, NY), galyfilcon A (Acuvue Advance; Johnson & Johnson Vision Care), lotrafilcon A and B (Nig

27 However, Amberg Johnson et al. (2017) identified the metalloprotease TgF

28 Cancer Research UK (C7627/A17938) and Johnson and Johnson Pharmaceuticals.

29 Chilcote and Johnson previously studied isolated Tetrahymena 22 S dyn

30 In their landmark study(1), Fecht and Johnson unveiled a phenomenon that they termed the 'entr

31 ression developed by Waugh and Fessenden and Johnson and Bovey only quantifies the contribution of ri

32 r Research UK (C7627/A17938) and Johnson and Johnson Pharmaceuticals.

33 However, Johnson and Johnson's vaccination was linked to 235 GBS after 60,256

34 Johnson and Johnson, Sputnik Light, and Moderna vaccines showed the

35 PIT, thrombin-saturated Gelfoam (Johnson and Johnson, Summerville, NJ) was embolized into the hepatic

36 , the slender body theories of Lighthill and Johnson, and the regularized Stokeslet method.

37 um Pharmaceuticals, Inc., Cambridge, MA, and Johnson & Johnson Pharmaceutical Research & Development,

38 Narasaka and Johnson pioneered the way in the use of nitrogen electro

39 mputerized cluster algorithm of Veldhuis and Johnson.

40 d by using an I-index proposed by Zimmer and Johnson.

41 haft, Koeln Fortune Program, Charles and Ann Johnson Foundation, Instituto de Salud Carlos III, Fondo

42 , Junta of Castile and Leon, Charles and Ann Johnson Foundation, Stanford Cancer Institute Innovation

43 In their recent article, Johnson and colleagues address this challenge by introdu

44 rmally induced electrical currents, known as Johnson noise, cause fluctuating electric and magnetic f

45 ions of fluoromethyl transfer agents such as Johnson's reagent.

46 rienced sonologists in Telescience Center at Johnson Space Center.

47 By using the recommended modified Becke-Johnson potential, we determine the electronic character

48 12 eyes, a Baerveldt glaucoma implant (BGI; Johnson & Johnson Surgical Vision) was implanted in 36 e

49 Ethicon, represented in Brazil by Johnson & Johnson do Brasil.

50 (C) RSNA, 2019 See also the editorial by Johnson in this issue.

51 romising approach presented in this issue by Johnson et al. is based on the idea of using pharmacolog

52 al survival, the recently published paper by Johnson et al., 'Ancient bacteria show evidence of DNA r

53 a new selection criterion developed by W. C. Johnson, Jr.

54 the predicted values using the widely cited Johnson and Christy data.

55 tion (MOR) on Ru/Pt thin film and commercial Johnson-Matthey PtRu/C, a revised MOR enhancement mechan

56 were 228 DES implanted (83% Cypher [Cordis, Johnson & Johnson, Warren, New Jersey], 17% Taxus [Bosto

57 Velocity stents ((BX Velocity/Sonic, Cordis, Johnson & Johnson) (BMS, n = 65), sirolimus-eluting sten

58 heduled per protocol by the 4 Cypher (Cordis/Johnson & Johnson, Warren, New Jersey) sirolimus-eluting

59 impact of batch effects on microarray data, Johnson, Rabinovic, and Li developed ComBat for use when

60 accumulation of conjugated bilirubin (Dubin-Johnson syndrome).

61 K. Fukuyama, S. S. Abdel-Meguid, J. E. Johnson, and M. G. Rossmann reported the structure of al

62 at paragraph, which now starts "For example, Johnson(10), Whiting(.)...".

63 ple being the inherent voltage fluctuations (Johnson noise) that exist across any resistor, which all

64 mpletion of PIT, thrombin-saturated Gelfoam (Johnson and Johnson, Summerville, NJ) was embolized into

65 athway of ATP hydrolysis follows the Gilbert-Johnson pathway determined previously for a similarsized

66 r major depressive disorder from the Ralph H Johnson Veterans Affairs Medical Center and four associa

67 Halpin, Johnson, and Miller contest our assignment of quantum be

68 3Lys, and was previously described as having Johnson-McMillin syndrome.

69 However, Johnson and Johnson's vaccination was linked to 235 GBS

70 In this issue of Immunity, Johnson et al.

71 In this issue of Immunity, Johnson et al. demonstrate a role for DC-expressed CD40L

72 zes the use-availability likelihood given in Johnson et al. (Resource selection functions based on us

73 However, while 9 of 27 such wells in Johnson County were near earthquakes, elsewhere no earth

74 eral implantation of the TECNIS Synergy IOL (Johnson & Johnson Surgical Vision) during a bilateral de

75 We used the isothermal Johnson-Mehl-Avrami-Kolmogorov (JMAK) model to estimate

76 In this issue, Johnson et al. reveal a heterogeneity in lysosomal pH an

77 In this issue, Johnson et al. shed light on this conundrum using a sing

78 In this issue, Johnson et al. show that a DNA glycosylase derived from

79 n & Johnson Vision) [System 2], TECNIS iTec (Johnson & Johnson Vision) [System 3], AutonoMe (Alcon, L

80 ollowing receipt of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccine.

81 straZeneca/Oxford) and Ad.26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccines.

82 adenovirus vector-based Ad26.COV2.S (Janssen/Johnson & Johnson) to mRNA-based BNT162b2 (Pfizer/BioNTe

83 novirus vector vaccine (Ad26.COV2.S (Janssen/Johnson & Johnson)).

84 S, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a human adenoviral vector

85 Jheannelle Johnson is a winner of the fifth annual Rising Black Sci

86 Johnson & Johnson stents were implanted in the SVGs of 186 patient

87 Johnson & Johnson; HIV Vaccine Trials Network; Division of AIDS, a

88 le, FL) and etafilcon A (Acuvue 2; Johnson & Johnson Vision Care) lenses were all soaked for 14 hours

89 ine or 1 dose of the JNJ-78436735 (Johnson & Johnson) vaccine.

90 sen Research & Development, LLC, a Johnson & Johnson company.

91 Lomb, Rochester, NY) and Acuvue2 (Johnson & Johnson, New Brunswick, NJ) soft contact lenses.

92 -HCl-soaked Acuvue lenses (Acuvue; Johnson & Johnson Vision Care, Inc., Jacksonville, FL).

93 NY), galyfilcon A (Acuvue Advance; Johnson & Johnson Vision Care), lotrafilcon A and B (Night & Day A

94 euticals, Inc., Cambridge, MA, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C., R

95 a Baerveldt glaucoma implant (BGI; Johnson & Johnson Surgical Vision) was implanted in 36 eyes, and a

96 Ethicon, represented in Brazil by Johnson & Johnson do Brasil.

97 tents ((BX Velocity/Sonic, Cordis, Johnson & Johnson) (BMS, n = 65), sirolimus-eluting stents (Cypher

98 DES implanted (83% Cypher [Cordis, Johnson & Johnson, Warren, New Jersey], 17% Taxus [Boston Scientif

99 r protocol by the 4 Cypher (Cordis/Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SE

100 ntation of the TECNIS Synergy IOL (Johnson & Johnson Surgical Vision) during a bilateral delayed sequ

101 n Vision) [System 2], TECNIS iTec (Johnson & Johnson Vision) [System 3], AutonoMe (Alcon, Laboratorie

102 eceipt of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccine.

103 /Oxford) and Ad.26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccines.

104 vector-based Ad26.COV2.S (Janssen/Johnson & Johnson) to mRNA-based BNT162b2 (Pfizer/BioNTech) in a c

105 ctor vaccine (Ad26.COV2.S (Janssen/Johnson & Johnson)).

106 6.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a human adenoviral vector, received

107 nts (23 eyes) with a Symfony lens (Johnson & Johnson Vision) were measured monocularly under red and

108 , GA), senofilcon A (Acuvue Oasys; Johnson & Johnson Vision Care, Jacksonville, FL) and etafilcon A (

109 , or ZA9003 (Abbott Medical Optics Johnson & Johnson Vision, Inc) IOLs were included in the study.

110 on of ZCB00 (Abbott Medical Optics Johnson & Johnson Vision, Inc, Abbott Park, Illinois, USA), SN60WF

111 1.122-1.704), receiving Pfizer or Johnson & Johnson versus Moderna, and multiple comorbidities.

112 ccinated with Pfizer's BNT162b2 or Johnson & Johnson's Ad26.CoV2.S and had BA.1 breakthrough infectio

113 ation system (TearScience, Inc, or Johnson & Johnson).

114 th one dose (of Pfizer/BioNTech or Johnson & Johnson).

115 9 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021.

116 ctor vaccines such as Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca).

117 at a dose of 100 mug, Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5x10(10) virus particles,

118 ord-AstraZeneca), and Ad26.COV2.S (Johnson & Johnson/Janssen).

119 NA-1273 [Moderna], or Ad26.COV2.S [Johnson & Johnson]) from December 11, 2020, through June 30, 2021,

120 er sirolimus-eluting stents (SES) (Johnson & Johnson, New Brunswick, New Jersey).

121 cs) [System 1], TECNIS Simplicity (Johnson & Johnson Vision) [System 2], TECNIS iTec (Johnson & Johns

122 er balloon injury, biliary stents (Johnson & Johnson) were implanted in the femoral arteries of 14 sw

123 d regenerated cellulose (Surgicel, Johnson & Johnson, New Brunswick, NJ), or pressure.

124 of a Tecnis monofocal IOL (ZCB00) (Johnson & Johnson Vision) were randomly assigned to have the optic

125 ayesian statistical techniques to update key Johnson-Ettinger input parameters, and we compare the pe

126 notation recently presented by Kirkpatrick, Johnson, and Barton (developed from previous work by Bar

127 Theoretically, we extend the well-known Johnson-Mehl-Avrami-Kolmogorov equation, which describes

128 , enabling the application of the Kolmogorov-Johnson-Mehl-Avrami equation to analyze the kinetics of

129 correction in Nicotiana benthamiana leaves (Johnson et al. in Plant Mol Biol 82(3):207-221, 2013).

130 akic patients (23 eyes) with a Symfony lens (Johnson & Johnson Vision) were measured monocularly unde

131 for its cement protein (CP) and HK97-like ('Johnson') for its major capsid protein (MCP).

132 this Quick guide, Holly Moeller and Matthew Johnson introduce Mesodinium, a genus of algae with a pr

133 Laboratories, Columbus, OH] and Casec [Mead-Johnson Nutritionals, Evansville, IN]; n = 18) diet.

134 We used a spatial acuity measure (Johnson-Van Boven-Phillips domes) to evaluate sensory sp

135 24-hour esophageal pH probe and had a median Johnson-DeMeester score of 10 (normal <22.0).

136 Ford Human Investigation Committee and NASA Johnson Space Center Committee for Protection of Human S

137 e, during, and after spaceflight at the NASA Johnson Space Center and International Space Station.

138 In this issue of Neuron, Johnson et al. (2019) report that inhibiting nonsense-me

139 In this issue of Neuron, Johnson et al. used whole-exome capture to identify VCP

140 has not been explored independent of Nyquist-Johnson noise until now.

141 We discover that unlike Nyquist-Johnson noise which has a uniform spectral density acros

142 on, Duluth, GA), senofilcon A (Acuvue Oasys; Johnson & Johnson Vision Care, Jacksonville, FL) and eta

143 Based on the approach of Johnson et al., I report for the first time the evolutio

144 calculations and validate the feasibility of Johnson's proposed mechanism.

145 exas, USA), or ZA9003 (Abbott Medical Optics Johnson & Johnson Vision, Inc) IOLs were included in the

146 implantation of ZCB00 (Abbott Medical Optics Johnson & Johnson Vision, Inc, Abbott Park, Illinois, US

147 cinated with one dose (of Pfizer/BioNTech or Johnson & Johnson).

148 ts were vaccinated with Pfizer's BNT162b2 or Johnson & Johnson's Ad26.CoV2.S and had BA.1 breakthroug

149 ly, and modeled using classical chemical, or Johnson-Mehl-Avrami-Kologoromov, kinetics.

150 ermal pulsation system (TearScience, Inc, or Johnson & Johnson).

151 3; 95% CI, 1.122-1.704), receiving Pfizer or Johnson & Johnson versus Moderna, and multiple comorbidi

152 the allergenic components of the Panicoideae Johnson grass pollen (JGP; Sorghum halepense).

153 ]-sigmatropic rearrangements, in particular, Johnson-Claisen and aromatic Claisen.

154 Exceptionally, for perfluorodecalin, Johnson-Kendall-Roberts mechanics was observed.

155 Three months after the case, President Johnson ratified the Civil Rights Act of 1964, which inc

156 nitrogen-vacancy centers in diamond to probe Johnson noise in the vicinity of conductive silver films

157 These methods were then used to reanalyze Johnson et al.'s neuron-restrictive silencer factor (NRS

158 witches and uses thermal noise in resistors (Johnson noise) to pump heat.

159 In this issue of Developmental Cell, Roh-Johnson et al. (2017) reveal that cytoplasmic transfer f

160 isease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021.

161 g viral vector vaccines such as Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca).

162 (Moderna) at a dose of 100 mug, Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5x10(10) virus p

163 AdOx1 (Oxford-AstraZeneca), and Ad26.COV2.S (Johnson & Johnson/Janssen).

164 NTech], mRNA-1273 [Moderna], or Ad26.COV2.S [Johnson & Johnson]) from December 11, 2020, through June

165 dry eye, Meesmann's dystrophy, and Steven's-Johnson syndrome.

166 W. S. Johnson's total synthesis of the sesquiterpenoid longifo

167 Employing high-sensitivity Johnson noise thermometry, we report an order of magnitu

168 ely spaced ions could continue to separate [ Johnson et al.

169 pping Cypher sirolimus-eluting stents (SES) (Johnson & Johnson, New Brunswick, New Jersey).

170 itoring the healing of damage on the shallow Johnson Valley fault after its rupture in the 1992 magni

171 These observations indicate that the shallow Johnson Valley fault is strengthening after the main sho

172 gical Optics) [System 1], TECNIS Simplicity (Johnson & Johnson Vision) [System 2], TECNIS iTec (Johns

173 After balloon injury, biliary stents (Johnson & Johnson) were implanted in the femoral arterie

174 Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T

175 Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T

176 Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T

177 Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)

178 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN

179 Stevens-Johnson syndrome and toxic epidermal necrolysis are seve

180 Stevens-Johnson syndrome is a well-recognized immune complex-med

181 ucocutaneous reaction described as a Stevens-Johnson syndrome that was attributed to chemotherapy.

182 ophthalmologic treatments for acute Stevens-Johnson syndrome (SJS) as well as the emerging treatment

183 ing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally assoc

184 , or type I, reactions, anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

185 = 2), increased lipase (n = 1), and Stevens-Johnson syndrome (n = 1).

186 relationship between HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T

187 Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) are rare, acute, life-threatening

188 drug-induced liver injury (DILI) and Stevens-Johnson syndrome (SJS) or toxic epidermal necrosis (TEN)

189 Toxic epidermal necrolysis and Stevens-Johnson syndrome are severe cutaneous drug reactions of

190 o corneal diseases, astigmatism, and Stevens-Johnson syndrome fall within corneal epithelial enhancer

191 (chemical injury in 9 [10 eyes] and Stevens-Johnson syndrome in 5 patients).

192 de in toxic epidermal necrolysis and Stevens-Johnson syndrome may cause the epidermal apoptosis and n

193 s-Johnson syndrome); myocarditis and Stevens-Johnson syndrome were considered related to pembrolizuma

194 malignant neoplasm progression, and Stevens-Johnson syndrome) and two patients treated with standard

195 neutropenic sepsis, myocarditis, and Stevens-Johnson syndrome); myocarditis and Stevens-Johnson syndr

196 and systemic symptoms syndrome, and Stevens-Johnson syndrome/toxic epidermal necrolysis, can be seve

197 o life-threatening reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T

198 ctions (DHR) induced by PPI, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)

199 aterally blind from diseases such as Stevens-Johnson syndrome, and ocular pemphigoid have little hope

200 ous adverse reaction (SCAR), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), h

201 chanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.

202 By comparison, Stevens-Johnson syndrome (SJS) is a life-threatening severe cuta

203 including the blistering conditions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T

204 for the life-threatening dermatoses Stevens-Johnson syndrome and toxic epidermal necrolysis.

205 s such as graft-versus-host disease, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

206 thy, lattice and Avellino dystrophy, Stevens-Johnson syndrome, and chemical/thermal injury.

207 According to the examination, Stevens-Johnson syndrome was diagnosed and the patient was admit

208 er preoperative diagnoses (excluding Stevens-Johnson syndrome, mucous membrane pemphigoid, and congen

209 ntibiotics are an important risk for Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN

210 Patients admitted for Stevens-Johnson syndrome/toxic epidermal necrolysis over a 14-ye

211 ntilation is required in one of four Stevens-Johnson syndrome/toxic epidermal necrolysis patients and

212 s with bronchiolitis obliterans from Stevens-Johnson syndrome often have progressive disease that may

213 icatricial pemphigoid>chemical burns>Stevens-Johnson syndrome.

214 ) lesions are frequently involved in Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN

215 adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T

216 nalyzed 74 cases of SCARs, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)

217 ition to carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)

218 LA-B*57:01 and carbamazepine-induced Stevens-Johnson syndrome and HLA-B*15:02 have been implemented i

219 associated with allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN

220 ndromes such as erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

221 such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and hypersensitivity syndrome.

222 keywords toxic epidermal necrolysis, Stevens-Johnson syndrome, photo-distributed, photo-induced, and

223 nsplantation (AMT) for severe ocular Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN)

224 Three cases of Stevens-Johnson Syndrome (SJS), and 11 cases of Drug Reaction wi

225 it is not clear whether the cause of Stevens-Johnson syndrome in COVID-19 patients is the virus itsel

226 , should be screened for symptoms of Stevens-Johnson syndrome.

227 Prompt identification of Stevens-Johnson syndrome/toxic epidermal necrolysis patients at

228 Cases of photodistributed Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T

229 n patients with actively progressing Stevens-Johnson syndrome or toxic epidermal necrolysis.

230 Although rare, Stevens-Johnson syndrome and toxic epidermal necrolysis remain a

231 ry group, and 10 (12 laminae) to the Stevens-Johnson syndrome (SJS) group.

232 r BCVA outcomes were observed in the Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)

233 In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, si

234 The underlying diseases were Stevens-Johnson syndrome (22 eyes), Sjogren syndrome (11 eyes),

235 common indications for surgery were Stevens-Johnson syndrome in 41.7% (20 of 48 eyes) and mucous mem

236 One patient with Stevens-Johnson syndrome and 2 patients with floppy eyelids had

237 els and the outcome of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

238 radically positive in a patient with Stevens-Johnson syndrome.

239 In the older (but not younger) subsample (Johnson-Neyman age cutoff of 46.7 years), craving during

240 1989 and in 1997 assumed the William and Sue Johnson Endowed Chair in Molecular Plant Pathology.

241 ), oxidized regenerated cellulose (Surgicel, Johnson & Johnson, New Brunswick, NJ), or pressure.

242 Surprisingly, Johnson et al. show that translation is uncoupled from t

243 unique, but all belong to the non-symmetric Johnson solid family, illustrating the potential of this

244 ng the leading and lagging strand templates (Johnson et al, 2015).

245 However, we find that Johnson noise is markedly suppressed next to single-crys

246 The Johnson-Kendall-Roberts (JKR) model was used to relate t

247 The Johnson-Kendall-Roberts theory is the basis of modern co

248 The Johnson-Mehl-Avrami model was used to determine the acti

249 component seismic arrays deployed across the Johnson Valley fault trace.

250 we show magnetic sensitivity approaching the Johnson-Nyquist noise limit of the system.

251 y of MCP is permuted non-circularly from the Johnson fold topology previously seen in viral and cellu

252 ead to a larger signal that emerges from the Johnson noise of the current amplifier.

253 Instead, the method modulates the Johnson (thermal) noise of a resistor to transmit inform

254 n approach for improving the accuracy of the Johnson-Ettinger model (JEM), which the Environmental Pr

255 are able to recover well-known limits of the Johnson-Kendall-Roberts theory, the Derjaguin-Muller-Top

256 strongly shook and permanently strained the Johnson Valley fault, adding damage discernible as a tem

257 Analysis using the Johnson-Kendall-Roberts, Derjaguin-Muller-Toporov, and H

258 We show that, whereas the Johnson-Kendall-Roberts theory holds for particles large

259 plate ion detectors are limited by thermal (Johnson) noise in the associated electronics.

260 ter and simpler measurement than traditional Johnson noise thermometry, making it potentially attract

261 en utilized in a Claisen rearrangement under Johnson's conditions to introduce a side chain that is f

262 verted question mark4-HPR, Fenretinide; R.W. Johnson Pharmaceutical Research Institute, Springhouse,

263 public sources aggregated in the Robert Wood Johnson County Health Rankings database.

264 pants were the 36 members of the Robert Wood Johnson Foundation (RWJF) Critical Care End-of-Life Peer

265 he American Community Survey and Robert Wood Johnson Foundation 500 Cities Project, which includes sc

266 Robert Wood Johnson Foundation and the U.S. Department of Veterans A

267 Robert Wood Johnson Foundation Clinical Scholars Program, National I

268 Robert Wood Johnson Foundation Clinical Scholars Program, National I

269 ns Health Administration and The Robert Wood Johnson Foundation Clinical Scholars Program.

270 Using data from the Robert Wood Johnson Foundation County Health Rankings, the United St

271 rlier and ongoing efforts of the Robert Wood Johnson Foundation Critical Care End-of-Life Peer Workgr

272 cal Faculty Development Program, Robert Wood Johnson Foundation grant 71590, the National Blood Found

273 Robert Wood Johnson Foundation Health and Society Scholars Program.

274 City of New York and the Robert Wood Johnson Foundation Healthy Eating Research program.

275 the future of primary care, the Robert Wood Johnson Foundation sponsored a meeting in October 2001 i

276 The Robert Wood Johnson Foundation's Pioneer Portfolio, Drane Family Fun

277 US Food and Drug Administration, Robert Wood Johnson Foundation, and Janssen Biotech.

278 onal Institute of Mental Health, Robert Wood Johnson Foundation, California Community Foundation, Nat

279 The Robert Wood Johnson Foundation, the Drane Family Fund, the Richard a

280 million national program of the Robert Wood Johnson Foundation, was developed to recruit leaders fro

281 Institute on Drug Abuse and the Robert Wood Johnson Foundation.

282 Commonwealth Fund and Robert Wood Johnson Foundation.

283 nal Institutes of Health and the Robert Wood Johnson Foundation.

284 hange, a national program of the Robert Wood Johnson Foundation.

285 nal Institute on Drug Abuse, and Robert Wood Johnson Foundation.

286 ncer Institute of New Jersey and Robert Wood Johnson Foundation.

287 me county rank as defined by the Robert Wood Johnson Foundation.

288 Primary Funding Source: Robert Wood Johnson Foundation.

289 partment of Veterans Affairs and Robert Wood Johnson Foundation.

290 ational Institutes of Health and Robert Wood Johnson Foundation.

291 (Funded in part by the Robert Wood Johnson Foundation.).

292 of Healthcare Quality Promotion; Robert Wood Johnson Foundation; US Department of Veterans Administra

293 ber Education grant program, the Robert Wood Johnson Pioneer Program, and the National Cancer Institu

294 skin antisepsis was performed at Robert Wood Johnson University Hospital (RWJUH).

295 2004 through 31 December 2005 at Robert Wood Johnson University Hospital and Duke University Medical

296 n measures of academic achievement (Woodcock Johnson), language (Comprehensive Assessment of Spoken L

297 est-Revised); academic achievement (Woodcock-Johnson Tests of Achievement-Revised); and parental repo

298 Test of Phonological Processing and Woodcock-Johnson reading batteries, respectively.

299 es, and Calculation subtests of the Woodcock-Johnson III Tests of Achievement (96+/-13 and 97+/-16; 1

300 psychological evaluations using the Woodcock-Johnson Tests of Cognitive Abilities Third Edition (medi

301 lantation of a Tecnis monofocal IOL (ZCB00) (Johnson & Johnson Vision) were randomly assigned to have